TC
CRSP icon

TwinBeech Capital’s CRISPR Therapeutics CRSP Stock Holding History

TwinBeech Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,072
Closed -$214K – 619
2025
Q4 		$214K Buy
+4,072
New +$244K 0.02% 530
2025
Q2 		– Sell
-31,578
Closed -$1.07M – 701
2025
Q1 		$1.07M Buy
+31,578
New +$1.34M 0.02% 476
2024
Q3 		– Sell
-146,473
Closed -$7.91M – 710
2024
Q2 		$7.91M Buy
+146,473
New +$8.47M 0.16% 170
2022
Q3 		– Sell
-37,247
Closed -$2.26M – 655
2022
Q2 		$2.26M Buy
+37,247
New +$2.19M 0.1% 203
2020
Q2 		– Sell
-7,412
Closed -$314K – 382
2020
Q1 		$314K Buy
+7,412
New +$383K 0.13% 220

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TwinBeech Capital's CRSP Position: Q1 2026 in Review

TwinBeech Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 4,072 shares — an estimated $214K sold.

TwinBeech Capital first reported a position in CRSP in Q1 2020 and held it in 5 quarters. The position peaked at $7.91M in Q2 2024. 492 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • TwinBeech Capital reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TwinBeech Capital sold 4,072 CRISPR Therapeutics shares in Q1 2026, an estimated $214K.
  • TwinBeech Capital first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 5 quarters.
  • TwinBeech Capital's CRISPR Therapeutics position peaked at $7.91M in Q2 2024.
  • 492 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.